How much funding has Traws Pharma raised?

Traws Pharma has raised $146.6M in total funding, most recently a Private Equity round.

Who are Traws Pharma's investors?

Traws Pharma's investors include OrbiMed, Sirenia Capital Management.

What industry is Traws Pharma in?

Traws Pharma operates in Biotech, Healthcare.

Traws Pharma

Targeting Critical Threats to Human Health

Biotech

Healthcare

Business Model: B2B
Website: trawspharma.com
Total Funding: $146.6M

Last Round: $60.0M Private EquityJan 2025
Rounds: 3

About

Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel oral small molecule therapies targeting respiratory viral diseases and cancer. The company is advancing two investigational antiviral candidates: Ratutrelvir, a ritonavir-independent COVID-19 treatment targeting the main protease, and Tivoxavir marboxil, a single-dose treatment for bird flu and seasonal influenza. Traws Pharma is publicly traded (Nasdaq: TRAW) and focuses on accelerated clinical strategies for vulnerable patient populations.

Summary

Traws Pharma is a Biotech company. It has raised $146.6M in total across 3 rounds, most recently a $60.0M Private Equity round in Jan 2025. Investors include OrbiMed and Sirenia Capital Management.